Tamoxifen and the female reproductive tract

REFERENCES

• JORDAN VC: The clinical development of tamoxifen. In: Tamoxifen: A Guide for Clinicians and Patients PRR, Huntington, NY, USA (1996):25–36.
   Google Scholar
• JORDAN VC, WOLF ME MIRECKI DM, WHITFORD DA, WELSHONS WV: Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. CRC Ctit. Rev Clin Lab. Sci. (1988) 26:97–152.
   Web of Science ®Google Scholar
• EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (1998) 351:1451-1467. ••An updated meta-analysis of 55randomised clinical trials of the effect of tamoxifen on breast cancer patients.
   Google Scholar
• NAYFIELD SG, KARP JE, FORD LG, DORR FA, KRAMER BS: Potential role of tamoxifen in prevention of breast cancer. Natl. Cancer Inst. (1991) 83:1450–1459.
   Google Scholar
• FRIEDMAN ZY: Recent advances in understanding the molecular mechanisms of tamoxifen action. Cancer Invest. (1998) 16:391–396.
   PubMed Web of Science ®Google Scholar
• FURR BJA, JORDAN VC: The pharmacology and clinical uses of tamoxifen. Pharmac. Ther. (1984) 25:127–205.
   PubMed Web of Science ®Google Scholar
• MANI C, GELBOIN HV, PARK SS et al: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed n-demethylation and 4-hydroxylation. Drug Metab. Dispos. (1993) 21:645–656.
   PubMed Web of Science ®Google Scholar
• STEARNS V, GELMANN EP: Does tamoxifen cause cancer in humans? Oricol. (1998) 16(2):779–792.
   Google Scholar
• JAIYESIMI IA, BUZDAR AU, DECKER DA, HORTOBAGYI GN: Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oricol. (1995) 13(2):513–529. •A comprehensive review of tamoxifen.
   Google Scholar
• LOVE RR, CAMERON L, CONNELL BL et al.: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch. Intern. Med. (1991) 151:1842–1847.
   PubMed Web of Science ®Google Scholar
• ENCK RE, RIOS CM: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer (1984) 53:2607–2609.
   PubMed Web of Science ®Google Scholar
• FORNANDER T, CEDERMARK B, MATTSSON A et al.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet (1989) 1:117-120. ••The first study to draw attention to theoccurrence of endometrial cancer in tamoxifen-treated breast cancer patients.
   Google Scholar
• POWLES TJ, JONES AL, ASHLEY SE et al.: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat. (1994) 31:73–82.
   PubMed Web of Science ®Google Scholar
• BOCCARDO F, BRUZZI P, RUBAGOTTI A etal.: Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology (1981) 38:281–285.
   Google Scholar
• LAHTI E, VUOPALA S, KAUPILLA A et al.: Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Cymru]. Oricol. (1994) 55:410–414.
   Google Scholar
• GILL BL, SIMPSON JF, SOMLO G, MCGONIGLE KE WILCZYNSKI SP: Effects of tamoxifen on the cytology of the uterine cervix in breast cancer patients. Diagn Cympathol. (1998) 19(6):417–422.
   PubMed Web of Science ®Google Scholar
• GOTTARDIS MM, ROBINSON SP, SATYASWAROOP PG, JORDAN VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. (1988) 48:812–815.
   PubMed Web of Science ®Google Scholar
• IACOBELLI S, SCAMBIA G, ATLANTE G etal.: Effect of tamoxifen on steroid hormone receptors and creatinine kinase activity in human endometrial carcinoma. Eur. J. Cancer Clin Oricol. (1986) 22:105–110.
   Google Scholar
• ELKAS J, GRAY K, HOWARD L et al: The effects of tamoxifen on endometrial insulin-like growth factor-1 expression. Obstet. Cymru]. (1998) 91(1):45–50.
   Google Scholar
• STACKIEVICZ R, DRUCKER L, RADNAY J et al.: Tamoxifen modulates apoptotic pathways in primary endometrial cell cultures. Clin Cancer Res. (2001) 7:415–420.
   PubMed Web of Science ®Google Scholar
• DILTS PV, Jr., HOPKINS MP, CHANG AE, CODY RL: Rapid growth of leiomyoma in a patient receiving tamoxifen. Am. J. Obstet. Cymru]. (1992) 166:167–168.
   PubMed Web of Science ®Google Scholar
• WOLF DM, JORDAN VC: Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Cymru]. Oricol. (1992) 45:118–128.
   Google Scholar
• ISMAIL SM: Gynaecological effects of tamoxifen. j Clin Thaw]. (1999) 52:83–88.
   Google Scholar
• ROSE PG, ALVAREZ B, MACLENNAN GT: Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure. Am. j Obstet. Cymru]. (2000) 183(2):507–508.
   PubMed Web of Science ®Google Scholar
• DELIGDISCH L, KALIR T, COHEN CJ etal.: Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Cymru]. Ontol. (2000) 78:181–186.
   Google Scholar
• KENNEDY MM, BAIGRIE CF, MANEK S: Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT related endometrial pathology. Int. I Cymru]. Pathol (1999) 18(2):130–137.
   PubMed Web of Science ®Google Scholar
• CLEMENT PB, OLIVA E, YOUNG RH: Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int. J. Crum]. Athol (1996) 15:222–229.
   Google Scholar
• UZIELY B, LEWIN A, BRUFMAN G, DOREMBUS D, MOR-YOSEF S: The effect of tamoxifen on the endometrium. Breast Cancer Res. Treat. (1993) 26:101–105.
   PubMed Web of Science ®Google Scholar
• DE MUYLDER X, NEVEN P, DE SOMER M et al.: Endometrial lesions in patients undergoing tamoxifen therapy. Int. Cymru]. Obstet. (1991) 36:127–130.
   Google Scholar
• KEDAR RP, BOURNE TH, POWLES TJ etal.: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 343:1318-1321. •One of few studies that describe the hormonal changes among tamoxifen-treated patients.
   Google Scholar
• HOOVER R, FRAUMENI JF, EVERSON R et al: Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet (1976) 1:885–887.
   PubMed Web of Science ®Google Scholar
• KILLACKEY MA, HAKES TB, PIERCE VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. (1985) 69(2):237–238. •The first case report of endometrial cancer among tamoxifen-treated breast cancer patients.
   Google Scholar
• SEOUD MA-F, JOHNSON J, WEED JC: Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Cymru]. (1993) 82(2):165–169.
   Google Scholar
• GAL D, KOPEL S, BASHEVKIN M et al.:Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer - preliminary report. Cynecol. Oncol. (1991) 42:120–123.
   PubMed Web of Science ®Google Scholar
• NEVEN P, DEMUYLDER X, VAN BELLE Y, VAN HOOFF I, VANDERICK G: Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet (1998) 351:36. •One of few prospective studies on the effect of tamoxifen on the endometrium.
   Google Scholar
• BERGMAN L, BEELEN MLR, GALLEE MPW et al.: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet (2000) 356:881–887.
   PubMed Web of Science ®Google Scholar
• VAN LEEUWEN FE, BENRAADT J, COEBERGH JWW et al.: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet (1994) 343:448–452.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN L, DEAPEN D, CERHAN JR et al.: Tamoxifen therapy for breast cancer and endometrial cancer risk. j Natl. Cancer Inst. (1999) 91(19):1654–1662.
   PubMedGoogle Scholar
• ROBINSON DC, BLOSS JD, SCHIANO MA: A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Cynecol. Oncol. (1995) 59:186–190.
   PubMed Web of Science ®Google Scholar
• FISHER B, COSTANTINO JP, REDMOND CK etal.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. _J. Natl. Cancer Inst. (1994) 86(7):527–537. ••A landmark prospective randomised studythat assesses the relative risk of endometrial cancer among tamoxifen-treated breast cancer patients.
   Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. I Nati Cancer Inst. (1998) 90(18):1371–1388. ••A landmark study of the value and sideeffects of tamoxifen as chemoprevention of breast cancer in high risk women.
   Google Scholar
• MIGNOTTE H, LASSET C, BONADONA V et al.: Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Intl Cancer (1998) 76:325-330. •A case-control study of the risk of endometrial cancer among women treated with tamoxifen.
   Google Scholar
• BERLIERE M, CHARLES A, GALANT C, DONNEZ J: Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet. Cyriecol. (1998) 91:40-44. •A longitudinal study that describes the significance of pre-tamoxifen endometrial changes on the development of significant endometrial lesions.
   Google Scholar
• MAGRIPLES U, NAFTOLIN F, SCHWARTZ PE, CARCANGIU ML: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. Chit. Oncol. (1993) 11(3):485–490. •The first report to claim a poor survival and aggressive tumours in endometrial cancers developing in tamoxifen-treated patients.
   Google Scholar
• ALTARAS MM, AVIRAM R, COHEN I et al.: Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Cynecol. Oncol. (1993) 49:255–258.
   PubMed Web of Science ®Google Scholar
• BOCKLAGE T, LEE KR, BELINSON JL:Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Cynecol. Oncol. (1992) 44:104–109.
   PubMed Web of Science ®Google Scholar
• MCCLUGGAGE WG, MCMANUS DT, LIOE TF, HILL CM: Uterine carcinosarcoma in association with tamoxifen therapy. Br I Obstet. Cynaecol. (1997) 104:748–750.
   PubMedGoogle Scholar
• MOURITS MJE, HOLLEMA H, WILLEMSE PHB et al.: Adenosarcoma of the uterus following tamoxifen for breast cancer. Int. J Cynecol. Cancer (1998) 8:168–171.
   Web of Science ®Google Scholar
• COHEN I, PEREL E, FLEX D et al.: Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. Chit. Pathol. (1999) 52:278–282.
   PubMed Web of Science ®Google Scholar
• DALLENBACH-HELLWEG G, SCHMIDT D, HELLBERG P et al.: The endometrium in breast cancer patients on tamoxifen. Arch. Cynecol. Obstet. (2000) 263:170–177.
   Google Scholar
• COHEN CJ: Tamoxifen and endometrialcancer: tamoxifen effects on the human female genital tract. Sem. Oncol. (1997) 24\(Suppl. 1):S1-55-S1–64.
   Google Scholar
• DECENSI A, FONTANA V, BRUNO S et al.: Effect of tamoxifen on endometrial proliferation. J. Chit. Oncol. (1996) 14(2):434–440.
   PubMed Web of Science ®Google Scholar
• CARMICHAEL PL, UGWUMADU AHN, NEVEN P etal.: Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. (1996) 56:1475–1479.
   Google Scholar
• HEMMINKI K, RAJANIEMI H, LINDAHL B et al.: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. (1996) 56:4374–4377.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ L: Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Eur. J Cancer (1998) 34\(Suppl. 4):523–34.
   Google Scholar
• KUWASHIMA Y, KUROSUMI M, KOBAYASHI Y et al.: Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma. Int. Cynecol. Pathol. (1998) 17:135–139.
   PubMed Web of Science ®Google Scholar
• ISAKSSON E, CLINE JM, SKOOG L et al.: p53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal Cynomolgus macques. Breast Cancer Res. Treat. (1999) 53:61–67.
   PubMed Web of Science ®Google Scholar
• GARDNER FJE, KONJE JC, ABRAMS KR etal.: Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet (2000) 356:1711–1717.
   Google Scholar
• BARAKAT RR, WONG G, CURTIN JP et al.: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Cynecol. Oncol. (1994) 55:164–168.
   PubMed Web of Science ®Google Scholar
• SILVA EG, TORNOS CS, FOLLEN-MITCHELL M: Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int. I Cynecol. Pathol. (1994) 13:248–258.
   PubMed Web of Science ®Google Scholar
• FORNANDER T, HELLSTROM A-C, MORBERGER B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. I Natl. Cancer Inst. (1993) 85:1850–1855.
   PubMed Web of Science ®Google Scholar
• SHUSHAN A, PERETZ T, UZIELY B, LEWIN A, MOR-YOSEF S: Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Obstet. Cynecol. (1996) 174(1):141–144.
   Google Scholar
• COHEN I, BEYTH Y, TEPPER R et al.:Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Cynecol. Oncol. (1996) 60:54–58.
   PubMed Web of Science ®Google Scholar
• MCGONIGLE KF, VASILEV SA, ODOM-MARYON T, SIMPSON JF: Ovarian histopathology in breast cancer patients receiving tamoxifen. Cyriecol Oricol (1999) 73:402–406.
   Google Scholar
• MOURITS MJE, DE VRIES EGE, WILLEMSE PHB etal.: Ovarian cysts in women receiving tamoxifen for breast cancer. Br. J. Cancer (1999) 79:1761–1764.
   Google Scholar
• SPICER DV, PIKE MC, HENDERSON BE: Ovarian cancer and long-term tamoxifen in premenopausal women. Lancet (1991) 337:1414.
   PubMed Web of Science ®Google Scholar
• SHERMAN BM, CHAPLER FK, CRICKARD K, WYCOFF D: Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. j Clin. Invest. (1979) 64:398–404.
   PubMed Web of Science ®Google Scholar
• HULKA CA, HALL DA: Endometrial abnormalities associated with tamoxifen therapy for breast cancer: songraphic and pathologic correlation. AR (1993) 160:809–812.
   PubMed Web of Science ®Google Scholar
• BORNSTEIN J, AUSLENDER R, PASCAL B et al: Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. j Reprod. Med. (1994) 39:674–678.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN SR: Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am. Obstet. Cyriecol (1994) 170(2):447–451.
   PubMed Web of Science ®Google Scholar
• ACHIRON R, LIPITZ S, SIVAN E, GOLDENBERG M, MASHIACH S: Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. j Ultrasound Med. (1995) 14:685–688.
   PubMed Web of Science ®Google Scholar
• ASCHER SM, JOHNSON JC, BARNES WA et al: MR imaging appearance of the uterus in postmenopausal women receiving tamoxifen therapy for breast cancer: histopathologic correlation. Radiology (1996) 200:105–110.
   PubMed Web of Science ®Google Scholar
• TEPPER R, BEYTH Y, ALTARAS MM et al.: Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Cyriecol Oricol (1997) 64:386–391.
   Google Scholar
• MOURITS MJE, VAN DER ZEE AGJ, WILLEMSE PHB etal.: Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Cyriecol Oricol (1999) 73:21–26.
   Google Scholar
• ASCHER SM, IMAOKA I, LAGE JM: Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology (2000) 214:29–38.
   PubMed Web of Science ®Google Scholar
• RAYTER Z, GAZET J-C, SHEPHERD Jetal.: Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur. &mg. Oricol (1994) 20:134–140.
   Google Scholar
• COHEN I, ROSEN DJD, SHAPIRA J etal.: Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Cyriecol. Oricol (1994) 52:185–190.
   Google Scholar
• MCGONIGLE KF, SHAW SL, VASILEV SA et al.: Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atropy. Am. j Obstet. Cyriecol (1998) 178:1145–1150.
   PubMed Web of Science ®Google Scholar
• NEVEN P, VERGOTE I: Should tamoxifenusers be screened for endometrial lesions? Lancet (1998) 351:155–157.
   PubMed Web of Science ®Google Scholar
• ALTHUIS MD, SEXTON M, LANGENBERG P et al: Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community- based study. Cancer (2000) 89(4):800–810. •A study that describes the current practice for suryeffiance for uterine abnormalities in tamoxifen users.
   Google Scholar
• AMERICAN COLLEGE OF OBSTETRICS AND GYNECOLOGY COMMITTEE ON GYNECOLOGIC PRACTICE: Tamoxifen and endometrial cancer. Committee Opinion (1996) 169:231–233.
   Google Scholar
• CHENG W-F, LIN H-H, TORNG P-L, HUANG S-C: Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Cyriecol Oricol (1997) 66:233–237.
   Google Scholar
• NEVEN P, DE MUYLDER X, VAN BELLE, Y, VANDERICK G, MUYLDER E: Tamoxifen and the uterus and endometrium. Lancet (1989) 1:375–376.
   PubMedGoogle Scholar
• LAHTI E, BLANCO G, KAUPPILA A etal.: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet. Cyriecol (1993) 81:660–664.
   Google Scholar
• SEOUD M, SHAMSEDDINE A, KHALIL A et al.: Tamoxifen and endometrial pathologies: a prospective study. Cyriecol. Oricol (1999) 75:15–19.
   Google Scholar
• BARAKAT RR, GILEWSKI TA, ALMADRONES L et al: Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. j Clin. Oricol (2000) 18:3459–3463.
   PubMed Web of Science ®Google Scholar